Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02028988 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide + External Beam Rt For Prostate
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02028988 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 64 participants.
The verdict
NCT02028988, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This research study is evaluating a drug called enzalutamide in combination with external beam radiation therapy as a possible treatment for prostate cancer. Presently, when participants receive hormonal therapy with radiation therapy for prostate cancer, medications are given to reduce testosterone levels in the blood stream. This leads to side effects such as loss of sex drive, erectile dysfunction (ED) and decrease in muscle strength. The purpose of this study is test another form of hormonal therapy with radiation therapy. The medication called enzalutamide will be used with radiation therapy. Instead of lowering testosterone, enzalutamide blocks testosterone in cells. This study will test if enzalutamide when used with radiation will lower the PSA without causing the side effects associated with medications that lower testosterone in the blood stream.
Interventions
- DRUG Enzalutamide
- RADIATION External Beam Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-02 |
| Est. Completion | 2018-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02028988
The ClinicalTrials.gov registry entry for NCT02028988 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enzalutamide is the first listed.
NCT02028988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02028988 about?
NCT02028988 is a clinical study titled "Enzalutamide + External Beam Rt For Prostate". This research study is evaluating a drug called enzalutamide in combination with external beam radiation therapy as a possible treatment for prostate cancer. Presently, when participants receive hormonal therapy with radiation therapy for prostate cancer, medications are given to reduce testosterone...
What is the current status of trial NCT02028988?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2014-02. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02028988?
The interventions under investigation include: Enzalutamide (DRUG), External Beam Radiation (RADIATION).
Who is sponsoring clinical trial NCT02028988?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.